Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001072613-25-000407)

Filing Details

Accession Number:: 0001072613-25-000407
Form Type:: 13G Filing
Publication Date:: 2025-05-14 20:00:00

Filed By:: ARCH Venture Fund X, L.P.
Company:: Maze Therapeutics Inc.
Filing Date:: 2025-05-15
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Beneficially Owned Number of Aggregate Shares	Percent of Class
ARCH Venture Fund X, L.P.	4,120,053	9.4%
ARCH Venture Fund X Overage, L.P.	4,120,053	9.4%
ARCH Venture Partners X, L.P.	4,120,053	9.4%
ARCH Venture Partners X Overage, L.P.	4,120,053	9.4%
ARCH Venture Partners X, LLC	4,120,053	9.4%
Keith Crandell	4,120,053	9.4%
Kristina Burow	4,120,053	9.4%
Steven Gillis	4,120,053	9.4%
Robert Nelsen	4,120,053	9.4%

Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Maze Therapeutics, Inc.

(Name of Issuer)

Common Stock par value $0.0001 per share

(Title of Class of Securities)

578784100

(CUSIP Number)

03/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

ARCH Venture Fund X, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

ARCH Venture Fund X Overage, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

ARCH Venture Partners X, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

ARCH Venture Partners X Overage, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

ARCH Venture Partners X, LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

Keith Crandell

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

Kristina Burow

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

Steven Gillis

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

578784100

Names of Reporting Persons

Robert Nelsen

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,120,053.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,120,053.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,120,053.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

9.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Maze Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080

Item 2.

(a)

Name of person filing:

ARCH Venture Fund X, L.P. ("AVF X"); ARCH Venture Partners X, L.P. ("AVP X LP"); ARCH Venture Partners X, LLC ("AVP X LLC"); ARCH Venture Fund X Overage, L.P. ("AVF X Overage"); ARCH Venture Partners X Overage, L.P. ("AVP X Overage GP") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen"), Kristina Burow ("Burow") and Steven Gillis ("Gillis) (collectively, the "Investment Committee" and individually, each a "Committee Member"). The Reporting Entities and the Committee Members collectively are referred to as the "Reporting Persons".

(b)

Address or principal business office or, if none, residence:

8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

(c)

Citizenship:

Each of AVF X, AVP X LP, AVF X Overage and AVP X Overage GP, are limited partnerships organized under the laws of the State of Delaware. AVP X LLC is a limited liability company organized under the laws of the State of Delaware. Each Committee Member is a US citizen.

(d)

Title of class of securities:

Common Stock par value $0.0001 per share

(e)

CUSIP No.:

578784100

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

AVF X is the record owner of 1,949,930 shares of Common Stock (the "AVF X Shares") as of March 31, 2025. AVP X LP, as the sole general partner of ARCH Venture Fund X, may be deemed to beneficially own the AVF X Shares. AVF X Overage is the record owner of 2,170,123 shares of Common Stock (the "AVF X Overage Shares"; combined with AVF X Shares, the "Record Shares") as of March 31, 2025. AVP X Overage GP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Shares. AVP X LLC, as the sole general partner of AVP X LP and AVP X Overage LP, may be deemed to beneficially own the Record Shares. As Committee Members of AVP X LLC, each Committee Member may also be deemed to share the power to direct the disposition and vote of the Record Shares.

(b)

Percent of class:

See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person is based upon 43,796,057 shares of common stock outstanding as of March 25, 2025 as reported on the Issuer's Form 10-K as filed with the Securities and Exchange Commission on March 31, 2025.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See line 5 of the cover sheets.

(ii) Shared power to vote or to direct the vote:

See line 6 of the cover sheets.

(iii) Sole power to dispose or to direct the disposition of:

See line 7 of the cover sheets.

(iv) Shared power to dispose or to direct the disposition of:

See line 8 of the cover sheets.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARCH Venture Fund X, L.P.

Signature:	ARCH Venture Partners X, L.P.
Name/Title:	its General Partner
Date:	05/15/2025

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	05/15/2025

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	05/15/2025

ARCH Venture Fund X Overage, L.P.

Signature:	ARCH Venture Partners X Overage, L.P.
Name/Title:	its General Partner
Date:	05/15/2025

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	05/15/2025

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	05/15/2025

ARCH Venture Partners X, L.P.

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	05/15/2025

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	05/15/2025

ARCH Venture Partners X Overage, L.P.

Signature:	ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	05/15/2025

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	05/15/2025

ARCH Venture Partners X, LLC

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	05/15/2025

Keith Crandell

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Date:	05/15/2025

Kristina Burow

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Kristina Burow
Date:	05/15/2025

Steven Gillis

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Steven Gillis
Date:	05/15/2025

Robert Nelsen

Signature:	/s/ Mark McDonnell
Name/Title:	* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
Date:	05/15/2025

Comments accompanying signature: * This Schedule 13G was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Verve Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on June 16, 2021 and incorporated herein in its entirety by reference.